Navigation Links
Research Report on BioClinica, Inc. as Speculative Buy

ATLANTA, Nov. 29 /PRNewswire/ -- The following is an investment opinion release issued by Intellivest Securities Research, Inc.

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries. A primary service is helping their clients manage, process and submit medical imaging portions of their submissions relating to their clinical trials to regulators, primarily the U.S. Food and Drug Administration and comparable European agencies, to evaluate product efficacy and safety. BioClinica has provided services to more than 130 firms in connection with over 2,000 clinical partners since its founding in 1990.

The Research Report rates BioClinica, Inc. as a Speculative Buy because the FDA and other regulators are encouraging more clinical trial data to be submitted in an electronic format. As an early mover in this area, BioClinica is well positioned to exploit this trend. BIOC has a strong balance sheet and an attractive valuation. It has no debt, adequate cash, growing positive cash flow and enjoys significant operating leverage. BioClinica's shares are currently trading around two times book value and one times revenue. It has an experienced, highly competent management team, who, along with Board members, own about 9% of outstanding shares. BIOC has worked with the world's leading bio-pharmaceutical companies including three that are Dow Jones Industrial Average components: Johnson & Johnson, Merck, and Pfizer.

BioClinica has recently completed the integration of its two most recent acquisitions both of which should be accretive in 2010. BIOC reported positive results for the third quarter ending 9/30.

The Report states that BioClinica faces a number of risks including the uncertainty facing the entire pharmaceutical industry as a result of proposed health reform legislation.

About the Report

Intellivest Securities Research, Inc.'s research is distributed by Intellivest Securities, Inc., (FINRA, SIPC, RIA, SIFMA), whose Office of Supervisory Jurisdiction is located at 1540 Chase Court, Riverdale, GA. 30296-2610. Please read the Research Report for certain disclaimers and disclosures. Daniel H. Kolber is the author of the Report and, a daily blog that aggregates articles about the Dow Jones 30 components (not affiliated with Dow Jones). He holds these licenses: Series 24, 27, 87, 53, 4, 79, 65; is a member of the Georgia, New York, Florida and Virginia Bars, and has the B.A. from Boston University, the J.D. from University of Virginia School of Law and the Ll.M. from New York University School of Law.

Intellivest Securities Research, Inc.'s (CRD #147288) research is distributed as third party research by its affiliate, Intellivest Securities, Inc. (CRD #145022) which is a member of the Financial Industry Regulatory Authority,.

SOURCE Intellivest Securities Research, Inc.

SOURCE Intellivest Securities Research, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Research sheds light on workings of anti-cancer drug
2. Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
3. MISSION Skincare(R) Supports GNCs Efforts To Raise Money for St. Jude Childrens Research Hospital(R)
4. Researchers identify proteins in lung cancer cells that may provide potential drug targets
5. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
6. Research Yields Clues to Severe Form of Sinusitis
7. AIDS research reveals a lack of family-planning programs in Uganda
8. Ann Taylor Stores Corp. Returns To St. Jude Childrens Research Hospitals Thanks and Giving Campaign(R) For The Third Year
9. New research shows versatility of amniotic fluid stem cells
10. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
11. Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... abuse located in central Michigan, have come together on Thanksgiving Day to share ... video, available for viewing on the Serenity Point YouTube channel, patients displayed what ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology: